Global Drug Repositioning Service Market 2026 driven by increasing age-related neurological disorders

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Drug Repositioning Service Market At The End Of The 2026–2030 Forecast Period?

The drug repositioning service market size has demonstrated robust growth in recent years. It is forecast to expand from $34.2 billion in 2025 to $36.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to escalating pharmaceutical research and development costs, the abundance of extensive legacy drug data, a growing number of unsuccessful clinical trials, the increasing demand for expedited drug development cycles, and the early adoption of computational approaches in drug discovery.

The drug repositioning service market size is anticipated to undergo significant growth in the coming years. It is projected to expand to $45.92 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.1%. This projected growth can be attributed to several factors, including increasing demand for cost-efficient drug development, the rising adoption of AI-driven discovery tools, a growing focus on rare and orphan diseases, the expansion of data-driven clinical research, and increasing regulatory acceptance of repurposed drugs. Key trends expected in the forecast period encompass the increasing use of AI-based drug repurposing platforms, a heightened focus on the re-evaluation of failed clinical drugs, the growing integration of real-world evidence in drug discovery, the expansion of precision medicine-oriented repositioning, and enhanced collaboration between pharmaceutical companies and CROs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29040&type=smp

What Primary Drivers Are Shaping The Development Of The Drug Repositioning Service Market?

The drug repositioning service market’s growth is projected to be propelled by an increase in healthcare expenditures. Healthcare expenditures refer to the entire sum of money allocated to health services, which includes preventative measures, treatment, rehabilitation, and administrative costs. This escalation in healthcare spending is primarily a result of rising medical expenses, influenced by technological advancements and the growing demand for healthcare provisions. Greater healthcare expenditure benefits drug repositioning services by making more funding available for clinical trials and research, which in turn accelerates the identification of new therapeutic applications for existing drugs. For example, in May 2024, the Office for National Statistics, a UK-based Government department, reported that total healthcare expenditure saw a notable rise of 5.6% in nominal terms from 2022 to 2023. Thus, the increasing healthcare expenditures are a key driver for the expansion of the drug repositioning service market.

What Segment Types Make Up The Drug Repositioning Service Market?

The drug repositioning service market covered in this report is segmented –

1) By Type: Generic Drugs, Clinical Trial Failed Drugs

2) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Other Therapeutic Area

3) By End-User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic Research Institutions, Hospitals And Ambulatory Surgical Centers.

Subsegments:

1) By Generic Drugs: Small Molecule Drugs, Biologics, Biosimilars, Peptide-Based Drugs

2) By Clinical Trial Failed Drugs: Phase I Failed Drugs, Phase II Failed Drugs, Phase III Failed Drugs, Safety-Related Failed Drugs, Efficacy-Related Failed Drugs

Which Market Trends Are Creating New Opportunities In The Drug Repositioning Service Market?

Leading firms in the drug repositioning service market are emphasizing the integration of artificial intelligence (AI) into drug repositioning, including the use of computational drug repositioning systems that systematically uncover novel therapeutic uses for existing medications through AI-powered analysis of scientific literature and biological information. Such a system is a technology-based platform that leverages artificial intelligence, machine learning, and data mining techniques to systematically examine existing drugs, compounds, and biological datasets. An example of this is the co-creation project launched in November 2024 by UBE and FRONTEO, two companies based in Japan. This collaborative framework combines the specialized knowledge of both UBE and FRONTEO, aiming to improve drug repositioning initiatives. It facilitates smooth collaboration between data analysis (dry research) and biological testing (wet research), thereby streamlining the progression from forming hypotheses to validating them experimentally. Utilizing FRONTEO’s AI-powered Drug Discovery AI Factory and KIBIT technology, the project systematically uncovers previously unrecorded connections between various diseases and molecules.

Who Are The Key Players Driving Competition In The Drug Repositioning Service Market?

Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited

Read the full drug repositioning service market report here:

https://www.thebusinessresearchcompany.com/report/drug-repositioning-service-global-market-report

How Does The Drug Repositioning Service Market Perform Across Major Global Regions?

North America was the largest region in the drug repositioning service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Drug Repositioning Service Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=29040&type=smp

Browse Through More Reports Similar to the Global Drug Repositioning Service Market 2026, By The Business Research Company

Drug Discovery Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Controlled Substance Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-substance-global-market-report

Behavioral Rehabilitation Market Report 2026

https://www.thebusinessresearchcompany.com/report/behavioral-rehabilitation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795